‘Warp Speed’ For Rare Diseases: Gene Therapy Pilot Also Includes Neurodegenerative Drugs

A plan developed by the US FDA biologics center to test ‘Operation Warp Speed’ style communication to support development of gene therapies is launching – and the scope has broadened to include drugs targeting ALS and other neurodegenerative diseases.

Warp Speed
• Source: Shutterstock

The US Food & Drug Administration will be offering “Operation Warp Speed” style interactions for up to six IND sponsors who are pursuing cell and gene therapies for rare pediatric disease or drugs for rare neurological disorders.

FDA announced the opportunity to participate its new Support for clinical Trials Advancing Rare disease Treatment, or START, pilot...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet